People living with HIV (PLWH) are diagnosed with cancer at an increased rate over the general population and generally have a higher mortality due to delayed diagnoses, advanced cancer stage, comorbidities, immunosuppression, and cancer treatment disparities. Lack of guidelines and provider education has led to substandard cancer care being offered to PLWH. To fill that gap, the NCCN Guidelines for Cancer in PLWH were developed; they provide treatment recommendations for PLWH who develop non–small cell lung cancer, anal cancer, Hodgkin lymphoma, and cervical cancer. In addition, the NCCN Guidelines outline advice regarding HIV management during cancer therapy; drug–drug interactions between antiretroviral treatments and cancer therapies; and workup, radiation therapy, surgical management, and supportive care in PLWH who have cancer.

Please NoteThe NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are a statement of consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representation or warranties of any kind regarding their content, use, or application and disclaims any responsibility for their applications or use in any way.© National Comprehensive Cancer Network, Inc. 2018, All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN.
Disclosures for the NCCN Cancer in People Living With HIV PanelAt the beginning of each NCCN Guidelines panel meeting, panel members review all potential conflicts of interest. NCCN, in keeping with its commitment to public transparency, publishes these disclosures for panel members, staff, and NCCN itself.Individual disclosures for the NCCN Cancer in People Living With HIV Panel members can be found on page 1017. (The most recent version of these guidelines and accompanying disclosures are available on the NCCN Web site at NCCN.org.)These guidelines are also available on the Internet. For the latest update, visit NCCN.org.
NCCN Cancer in People Living With HIV Panel Members*Erin Reid, MD/Co-Chair‡UC San Diego Moores Cancer Center*Gita Suneja, MD/Co-Chair§Duke Cancer Institute*Richard F. Ambinder, MD, PhD†The Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsKevin Ard, MD, MPHΦÞMassachusetts General Hospital Cancer CenterRobert Baiocchi, MD, PhD†The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute*Stefan K. Barta, MD, MS, MRCP†‡ÞFox Chase Cancer Center*Evie Carchman, MD¶University of Wisconsin Carbone Cancer CenterAdam Cohen, MD†Huntsman Cancer Institute at the University of UtahNeel Gupta, MD†Stanford Cancer Institute*Kimberly L. Johung, MD, PhD§Yale Cancer Center/Smilow Cancer HospitalAnn Klopp, MD, PhD§The University of Texas MD Anderson Cancer CenterAnn S. LaCasce, MD†Dana-Farber/Brigham and Women's Cancer CenterChi Lin, MD§Fred & Pamela Buffett Cancer CenterOxana V. Makarova-Rusher, MD†University of Michigan Rogel Cancer CenterAmitkumar Mehta, MD‡University of Alabama at Birmingham Comprehensive Cancer Center*Manoj P. Menon, MD, MPH†Fred Hutchinson Cancer Research Center/Seattle Cancer Care AllianceDavid Morgan, MD‡Vanderbilt-Ingram Cancer CenterNitya Nathwani, MD‡City of Hope Comprehensive Cancer Center*Ariela Noy, MD‡Memorial Sloan Kettering Cancer CenterFrank Palella, MDRobert H. Lurie Comprehensive Cancer Center of Northwestern University*Lee Ratner, MD, PhD†ÞSiteman Cancer Center at Barnes-Jewish Hospital and Washington University School of MedicineStacey Rizza, MDΦMayo Clinic Cancer Center*Michelle A. Rudek, PhD, PharmDΣThe Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsJeff Taylor¥HIV + Aging Research Project - Palm SpringsBenjamin Tomlinson, MD†‡Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute*Chia-Ching J. Wang, MD†UCSF Helen Diller Family Comprehensive Cancer CenterNCCN Staff: Mary A. Dwyer, MS, and Deborah A. Freedman-Cass, PhD*Discussion Section Writing CommitteeSpecialties: †Medical Oncology; ‡Hematology/Hematology Oncology; §Radiotherapy/Radiation Oncology; ¶Surgery/Surgical Oncology; ÞInternal Medicine; ΣPharmacology/Pharmacy; ΦInfectious Diseases; ¥Patient Advocacy
  • 1.

    U.S. Statistics. HIV.gov; 2017. Available at: https://www.hiv.gov/hiv-basics/overview/data-and-trends/statistics. Accessed August 16 2017.

    • Search Google Scholar
    • Export Citation
  • 2.

    GoedertJJCoteTRVirgoP. Spectrum of AIDS-associated malignant disorders. Lancet1998;351:18331839.

  • 3.

    FrischMBiggarRJEngelsEA. Association of cancer with AIDS-related immunosuppression in adults. JAMA2001;285:17361745.

  • 4.

    Antiretroviral Therapy Cohort Collaboration. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV2017;4:e349356.

    • Search Google Scholar
    • Export Citation
  • 5.

    DetelsRMunozAMcFarlaneG. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA1998;280:14971503.

    • Search Google Scholar
    • Export Citation
  • 6.

    PalellaFJJrDelaneyKMMoormanAC. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med1998;338:853860.

    • Search Google Scholar
    • Export Citation
  • 7.

    CobucciRNLimaPHde SouzaPC. Assessing the impact of HAART on the incidence of defining and non-defining AIDS cancers among patients with HIV/AIDS: a systematic review. J Infect Public Health2015;8:110.

    • Search Google Scholar
    • Export Citation
  • 8.

    EngelsEAPfeifferRMGoedertJJ. Trends in cancer risk among people with AIDS in the United States 1980–2002. AIDS2006;20:16451654.

  • 9.

    EngelsEABiggarRJHallHI. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer2008;123:187194.

    • Search Google Scholar
    • Export Citation
  • 10.

    PatelPHansonDLSullivanPS. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med2008;148:728736.

    • Search Google Scholar
    • Export Citation
  • 11.

    RobbinsHAShielsMSPfeifferRMEngelsEA. Epidemiologic contributions to recent cancer trends among HIV-infected people in the United States. AIDS2014;28:881890.

    • Search Google Scholar
    • Export Citation
  • 12.

    ShielsMSPfeifferRMGailMH. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst2011;103:753762.

  • 13.

    RobbinsHAPfeifferRMShielsMS. Excess cancers among HIV-infected people in the United States. J Natl Cancer Inst2015;107:pii: dju503.

  • 14.

    AngelettiPCZhangLWoodC. The viral etiology of AIDS-associated malignancies. Adv Pharmacol2008;56:509557.

  • 15.

    ChaturvediAKMadeleineMMBiggarRJEngelsEA. Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst2009;101:11201130.

    • Search Google Scholar
    • Export Citation
  • 16.

    GrulichAEvan LeeuwenMTFalsterMOVajdicCM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet2007;370:5967.

    • Search Google Scholar
    • Export Citation
  • 17.

    Hernandez-RamirezRUShielsMSDubrowREngelsEA. Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study. Lancet HIV2017;4:e495504.

    • Search Google Scholar
    • Export Citation
  • 18.

    MeijideHPertegaSRodriguez-OsorioI. Increased incidence of cancer observed in HIV/hepatitis C virus-coinfected patients versus HIV-monoinfected. AIDS2017;15:10991107.

    • Search Google Scholar
    • Export Citation
  • 19.

    TesorieroJMGieryicSMCarrascalALavigneHE. Smoking among HIV positive New Yorkers: prevalence, frequency, and opportunities for cessation. AIDS Behav2010;14:824835.

    • Search Google Scholar
    • Export Citation
  • 20.

    HellebergMAfzalSKronborgG. Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study. Clin Infect Dis2013;56:727734.

    • Search Google Scholar
    • Export Citation
  • 21.

    McGinnisKAFultzSLSkandersonM. Hepatocellular carcinoma and non-Hodgkin's lymphoma: the roles of HIV, hepatitis C infection, and alcohol abuse. J Clin Oncol2006;24:50055009.

    • Search Google Scholar
    • Export Citation
  • 22.

    ParkLSHernandez-RamirezRUSilverbergMJ. Prevalence of non-HIV cancer risk factors in persons living with HIV/AIDS: a meta-analysis. AIDS2016;30:273291.

    • Search Google Scholar
    • Export Citation
  • 23.

    RentschCTateJPAkgunKM. Alcohol-related diagnoses and all-cause hospitalization among HIV-infected and uninfected patients: a longitudinal analysis of United States veterans from 1997 to 2011. AIDS Behav2016;20:555564.

    • Search Google Scholar
    • Export Citation
  • 24.

    U.S. National Library of Medicine-Key MEDLINE Indicators. Available at: http://www.nlm.nih.gov/bsd/bsd_key.html. Accessed August 15 2017.

    • Search Google Scholar
    • Export Citation
  • 25.

    BiggarRJEngelsEALyS. Survival after cancer diagnosis in persons with AIDS. J Acquir Immune Defic Syndr2005;39:293299.

  • 26.

    CoghillAEShielsMSSunejaGEngelsEA. Elevated cancer-specific mortality among HIV-infected patients in the United States. J Clin Oncol2015;33:23762383.

    • Search Google Scholar
    • Export Citation
  • 27.

    CoghillAEPfeifferRMShielsMSEngelsEA. Excess mortality among HIV-infected individuals with cancer in the United States. Cancer Epidemiol Biomarkers Prev2017;26:10271033.

    • Search Google Scholar
    • Export Citation
  • 28.

    MarcusJLChaoCLeydenWA. Survival among HIV-infected and HIV-uninfected individuals with common non-AIDS-defining cancers. Cancer Epidemiol Biomarkers Prev2015;24:11671173.

    • Search Google Scholar
    • Export Citation
  • 29.

    BrockMVHookerCMEngelsEA. Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: implications for patient care. J Acquir Immune Defic Syndr2006;43:4755.

    • Search Google Scholar
    • Export Citation
  • 30.

    FerreiraMPCoghillAEChavesCB. Outcomes of cervical cancer among HIV-infected and HIV-uninfected women treated at the Brazilian National Institute of Cancer. AIDS2017;31:523531.

    • Search Google Scholar
    • Export Citation
  • 31.

    Dryden-PetersonSBvochora-NsingoMSunejaG. HIV infection and survival among women with cervical cancer. J Clin Oncol2016;34:37493757.

  • 32.

    SunejaGLinCCSimardEP. Disparities in cancer treatment among patients infected with the human immunodeficiency virus. Cancer2016;122:23992407.

    • Search Google Scholar
    • Export Citation
  • 33.

    SunejaGShielsMSAnguloR. Cancer treatment disparities in HIV-infected individuals in the United States. J Clin Oncol2014;32:23442350.

    • Search Google Scholar
    • Export Citation
  • 34.

    SunejaGBoyerMYehiaBR. Cancer treatment in patients with HIV infection and non-AIDS-defining cancers: a survey of US oncologists. J Oncol Pract2015;11:e380387.

    • Search Google Scholar
    • Export Citation
  • 35.

    MarksGCrepazNSenterfittJWJanssenRS. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr2005;39:446453.

    • Search Google Scholar
    • Export Citation
  • 36.

    BransonBMHandsfieldHHLampeMA. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep2006;55:117; quiz CE11–14.

    • Search Google Scholar
    • Export Citation
  • 37.

    ChiaoEYDezubeBJKrownSE. Time for oncologists to opt in for routine opt-out HIV testing?JAMA2010;304:334339.

  • 38.

    HwangJPGranwehrBPTorresHA. HIV testing in patients with cancer at the initiation of therapy at a large US comprehensive cancer center. J Oncol Pract2015;11:384390.

    • Search Google Scholar
    • Export Citation
  • 39.

    LiJThompsonTDTaiE. Testing for human immunodeficiency virus among cancer survivors under age 65 in the United States. Prev Chronic Dis2014;11:E200.

    • Search Google Scholar
    • Export Citation
  • 40.

    HIV Care Continuum. HIV.gov; 2017. Available at: https://www.hiv.gov/federal-response/policies-issues/hiv-aids-care-continuum. Accessed August 16 2017.

    • Search Google Scholar
    • Export Citation
  • 41.

    FlashCAPasalarSHemmigeV. Benefits of a routine opt-out HIV testing and linkage to care program for previously diagnosed patients in publicly funded emergency departments in Houston, TX. J Acquir Immune Defic Syndr2015;69(Suppl 1):S815.

    • Search Google Scholar
    • Export Citation
  • 42.

    IrvineMKChamberlinSARobbinsRS. Improvements in HIV care engagement and viral load suppression following enrollment in a comprehensive HIV care coordination program. Clin Infect Dis2015;60:298310.

    • Search Google Scholar
    • Export Citation
  • 43.

    KitahataMMGangeSJAbrahamAG. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med2009;360:18151826.

    • Search Google Scholar
    • Export Citation
  • 44.

    SilverbergMJNeuhausJBowerM. Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS2007;21:19571963.

  • 45.

    El-SadrWMLundgrenJNeatonJD. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med2006;355:22832296.

  • 46.

    HessolNAPipkinSSchwarczS. The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. Am J Epidemiol2007;165:11431153.

    • Search Google Scholar
    • Export Citation
  • 47.

    GerardLGalicierLMaillardA. Systemic non-Hodgkin lymphoma in HIV-infected patients with effective suppression of HIV replication: persistent occurrence but improved survival. J Acquir Immune Defic Syndr2002;30:478484.

    • Search Google Scholar
    • Export Citation
  • 48.

    Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. AIDSinfo; 2016. Available at: https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed August 16 2017.

    • Search Google Scholar
    • Export Citation
  • 49.

    TorresHAMulanovichV. Management of HIV infection in patients with cancer receiving chemotherapy. Clin Infect Dis2014;59:106114.

  • 50.

    BuchaczKBakerRKPalellaFJJr. AIDS-defining opportunistic illnesses in US patients, 1994-2007: a cohort study. AIDS2010;24:15491559.

  • 51.

    LedergerberBEggerMErardV. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA1999;282:22202226.

    • Search Google Scholar
    • Export Citation
  • 52.

    SchwarczLChenMJVittinghoffE. Declining incidence of AIDS-defining opportunistic illnesses: results from 16 years of population-based AIDS surveillance. AIDS2013;27:597605.

    • Search Google Scholar
    • Export Citation
  • 53.

    DjaweKBuchaczKHsuL. Mortality risk after AIDS-defining opportunistic illness among HIV-infected persons—San Francisco, 1981–2012. J Infect Dis2015;212:13661375.

    • Search Google Scholar
    • Export Citation
  • 54.

    BorgCRay-CoquardIPhilipI. CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer. Cancer2004;101:26752680.

    • Search Google Scholar
    • Export Citation
  • 55.

    DaleDCMcCarterGCCrawfordJLymanGH. Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials. J Natl Compr Canc Netw2003;1:440454.

    • Search Google Scholar
    • Export Citation
  • 56.

    SeropianSNadkarniRJillellaAP. Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option. Bone Marrow Transplant1999;23:599605.

    • Search Google Scholar
    • Export Citation
  • 57.

    SavageDGLindenbaumJGarrettTJ. Biphasic pattern of bacterial infection in multiple myeloma. Ann Intern Med1982;96:4750.

  • 58.

    GriffithsHLeaJBunchC. Predictors of infection in chronic lymphocytic leukaemia (CLL). Clin Exp Immunol1992;89:374377.

  • 59.

    BodeyGPBuckleyMSatheYSFreireichEJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med1966;64:328340.

    • Search Google Scholar
    • Export Citation
  • 60.

    SchimpffSC. Empiric antibiotic therapy for granulocytopenic cancer patients. Am J Med1986;80:1320.

  • 61.

    MorrisonVA. Immunosuppression associated with novel chemotherapy agents and monoclonal antibodies. Clin Infect Dis2014;59(Suppl 5):S360364.

    • Search Google Scholar
    • Export Citation
  • 62.

    NgidiSMagulaNSartoriusB. Incidence of chemotherapy-induced neutropenia in HIV-infected and uninfected patients with breast cancer receiving neoadjuvant chemotherapy. S Afr Med J2017;107:595601.

    • Search Google Scholar
    • Export Citation
  • 63.

    ParkJKimTMHwangJH. Risk factors for febrile neutropenia during chemotherapy for HIV-related lymphoma. J Korean Med Sci2012;27:14681471.

    • Search Google Scholar
    • Export Citation
  • 64.

    SparanoJAHuXWiernikPH. Opportunistic infection and immunologic function in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma treated with chemotherapy. J Natl Cancer Inst1997;89:301307.

    • Search Google Scholar
    • Export Citation
  • 65.

    WangESStrausDJTeruya-FeldsteinJ. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer2003;98:11961205.

    • Search Google Scholar
    • Export Citation
  • 66.

    BaserSShannonVREapenGA. Smoking cessation after diagnosis of lung cancer is associated with a beneficial effect on performance status. Chest2006;130:17841790.

    • Search Google Scholar
    • Export Citation
  • 67.

    ParsonsADaleyABeghRAveyardP. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ2010;340:b5569.

    • Search Google Scholar
    • Export Citation
  • 68.

    MasonDPSubramanianSNowickiER. Impact of smoking cessation before resection of lung cancer: a Society of Thoracic Surgeons General Thoracic Surgery Database study. Ann Thorac Surg2009;88:362370.

    • Search Google Scholar
    • Export Citation
  • 69.

    KhuriFRKimESLeeJJ. The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. Cancer Epidemiol Biomarkers Prev2001;10:823829.

    • Search Google Scholar
    • Export Citation
  • 70.

    RoachMCRehmanSDeWeesTA. It's never too late: smoking cessation after stereotactic body radiation therapy for non-small cell lung carcinoma improves overall survival. Pract Radiat Oncol2016;6:1218.

    • Search Google Scholar
    • Export Citation
  • 71.

    Dobson AmatoKAHylandAReedR. Tobacco cessation may improve lung cancer patient survival. J Thorac Oncol2015;10:10141019.

  • 72.

    RichardsonGETuckerMAVenzonDJ. Smoking cessation after successful treatment of small-cell lung cancer is associated with fewer smoking-related second primary cancers. Ann Intern Med1993;119:383390.

    • Search Google Scholar
    • Export Citation
  • 73.

    KuriMNakagawaMTanakaH. Determination of the duration of preoperative smoking cessation to improve wound healing after head and neck surgery. Anesthesiology2005;102:892896.

    • Search Google Scholar
    • Export Citation
  • 74.

    DavisonJMSubramaniamRMSurasiDS. FDG PET/CT in patients with HIV. AJR Am J Roentgenol2011;197:284294.

  • 75.

    GoodmanPC. Radiographic assessment of HIV-associated diseases. HIV InSite2006. Available at: http://hivinsite.ucsf.edu/InSite?page=kb-00&doc=kb-04-01-16. Accessed July 24 2018.

    • Search Google Scholar
    • Export Citation
  • 76.

    ScharkoAMPerlmanSBPyzalskiRW. Whole-body positron emission tomography in patients with HIV-1 infection. Lancet2003;362:959961.

  • 77.

    BrustDPolisMDaveyR. Fluorodeoxyglucose imaging in healthy subjects with HIV infection: impact of disease stage and therapy on pattern of nodal activation. AIDS2006;20:985993.

    • Search Google Scholar
    • Export Citation
  • 78.

    GoshenEDavidsonTAvigdorA. PET/CT in the evaluation of lymphoma in patients with HIV-1 with suppressed viral loads. Clin Nucl Med2008;33:610614.

    • Search Google Scholar
    • Export Citation
  • 79.

    AllenCMAl-JahdaliHHIrionKL. Imaging lung manifestations of HIV/AIDS. Ann Thorac Med2010;5:201216.

  • 80.

    GingoMRMorrisA. Pathogenesis of HIV and the lung. Curr HIV/AIDS Rep2013;10:4250.

  • 81.

    LangfordTDLetendreSLLarreaGJMasliahE. Changing patterns in the neuropathogenesis of HIV during the HAART era. Brain Pathol2003;13:195210.

    • Search Google Scholar
    • Export Citation
  • 82.

    GottumukkalaRVRomeroJMRiascosRF. Imaging of the brain in patients with human immunodeficiency virus infection. Top Magn Reson Imaging2014;23:275291.

    • Search Google Scholar
    • Export Citation
  • 83.

    SathekgeMMaesAVan de WieleC. FDG-PET imaging in HIV infection and tuberculosis. Semin Nucl Med2013;43:349366.

  • 84.

    RestrepoCSLemosDFGordilloH. Imaging findings in musculoskeletal complications of AIDS. Radiographics2004;24:10291049.

  • 85.

    MangioniDBanderaAMuscatelloA. Focal bone lesions in HIV-positive patient treated with tenofovir. BMC Infect Dis2014;14:131.

  • 86.

    YeeJWallSD. Gastrointestinal manifestations of AIDS. Gastroenterol Clin North Am1995;24:413434.

  • 87.

    LefkowitchJH. Pathology of AIDS-related liver disease. Dig Dis1994;12:321330.

  • 88.

    SparanoJAWiernikPHHuX. Saquinavir enhances the mucosal toxicity of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma. Med Oncol1998;15:5057.

    • Search Google Scholar
    • Export Citation
  • 89.

    RudekMAFlexnerCAmbinderRF. Use of antineoplastic agents in patients with cancer who have HIV/AIDS. Lancet Oncol2011;12:905912.

  • 90.

    LarsonKBWangKDelilleC. Pharmacokinetic enhancers in HIV therapeutics. Clin Pharmacokinet2014;53:865872.

  • 91.

    DeekenJFBeumerJHAndersNM. Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib. Cancer Chemother Pharmacol2015;76:813819.

    • Search Google Scholar
    • Export Citation
  • 92.

    RudekMAChangCYSteadmanK. Combination antiretroviral therapy (cART) component ritonavir significantly alters docetaxel exposure. Cancer Chemother Pharmacol2014;73:729736.

    • Search Google Scholar
    • Export Citation
  • 93.

    RudekMAMoorePCMitsuyasuRT. A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061. Cancer2014;120:11941202.

    • Search Google Scholar
    • Export Citation
  • 94.

    RubinsteinPGBraikTJainS. Ritonavir based highly active retroviral therapy (HAART) correlates with early neurotoxicity when combined with ABVD treated HIV associated Hodgkin lymphoma but not non-Hodgkin lymphoma. A retrospective study [abstract]. Blood2010;116:Abstract 2807.

    • Search Google Scholar
    • Export Citation
  • 95.

    CasadoJLMachucaIBanonS. Raltegravir plus two nucleoside analogues as combination antiretroviral therapy in HIV-infected patients who require cancer chemotherapy. Antivir Ther2015;20:773777.

    • Search Google Scholar
    • Export Citation
  • 96.

    TorresHARallapalliVSaxenaA. Efficacy and safety of antiretrovirals in HIV-infected patients with cancer. Clin Microbiol Infect2014;20:O672679.

    • Search Google Scholar
    • Export Citation
  • 97.

    MoyleGJSadlerM. Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence and management. Drug Saf1998;19:481494.

    • Search Google Scholar
    • Export Citation
  • 98.

    BowerMMcCall-PeatNRyanN. Protease inhibitors potentiate chemotherapy-induced neutropenia. Blood2004;104:29432946.

  • 99.

    BowerMPowlesTStebbingJThirlwellC. Potential antiretroviral drug interactions with cyclophosphamide, doxorubicin, and etoposide. J Clin Oncol2005;23:13281329; author reply 1329–1330.

    • Search Google Scholar
    • Export Citation
  • 100.

    HughesCARobinsonLTsengAMacArthurRD. New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir. Expert Opin Pharmacother2009;10:24452466.

    • Search Google Scholar
    • Export Citation
  • 101.

    LyTRuizME. Prolonged QT interval and torsades de pointes associated with atazanavir therapy. Clin Infect Dis2007;44:e6768.

  • 102.

    BehrensGDejamASchmidtH. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS1999;13:F6370.

    • Search Google Scholar
    • Export Citation
  • 103.

    HoffmanRWeltonMLKlenckeB. The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer. Int J Radiat Oncol Biol Phys1999;44:127131.

    • Search Google Scholar
    • Export Citation
  • 104.

    HollandJMSwiftPS. Tolerance of patients with human immunodeficiency virus and anal carcinoma to treatment with combined chemotherapy and radiation therapy. Radiology1994;193:251254.

    • Search Google Scholar
    • Export Citation
  • 105.

    KimJHSaraniBOrkinBA. HIV-positive patients with anal carcinoma have poorer treatment tolerance and outcome than HIV-negative patients. Dis Colon Rectum2001;44:14961502.

    • Search Google Scholar
    • Export Citation
  • 106.

    AlongiFGiaj-LevraNSciasciaS. Radiotherapy in patients with HIV: current issues and review of the literature. Lancet Oncol2017;18:e379393.

    • Search Google Scholar
    • Export Citation
  • 107.

    ChiaoEYGiordanoTPRichardsonPEl-SeragHB. Human immunodeficiency virus-associated squamous cell cancer of the anus: epidemiology and outcomes in the highly active antiretroviral therapy era. J Clin Oncol2008;26:474479.

    • Search Google Scholar
    • Export Citation
  • 108.

    SeoYKinsellaMTReynoldsHL. Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients. Int J Radiat Oncol Biol Phys2009;75:143149.

    • Search Google Scholar
    • Export Citation
  • 109.

    LordRV. Anorectal surgery in patients infected with human immunodeficiency virus: factors associated with delayed wound healing. Ann Surg1997;226:9299.

    • Search Google Scholar
    • Export Citation
  • 110.

    BurkeECOrloffSLFreiseCE. Wound healing after anorectal surgery in human immunodeficiency virus-infected patients. Arch Surg1991;126:12671270.

    • Search Google Scholar
    • Export Citation
  • 111.

    BuehrerJLWeberDJMeyerAA. Wound infection rates after invasive procedures in HIV-1 seropositive versus HIV-1 seronegative hemophiliacs. Ann Surg1990;211:492498.

    • Search Google Scholar
    • Export Citation
  • 112.

    HorbergMAHurleyLBKleinDB. Surgical outcomes in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. Arch Surg2006;141:12381245.

    • Search Google Scholar
    • Export Citation
  • 113.

    Alfa-WaliMDalla PriaANelsonM. Surgical excision alone for stage T1 anal verge cancers in people living with HIV. Eur J Surg Oncol2016;42:813816.

    • Search Google Scholar
    • Export Citation
  • 114.

    LeedsILAlturkiHCannerJK. Outcomes of abdominoperineal resection for management of anal cancer in HIV-positive patients: a national case review. World J Surg Oncol2016;14:208.

    • Search Google Scholar
    • Export Citation
  • 115.

    LefevreJHCorteHTiretE. Abdominoperineal resection for squamous cell anal carcinoma: survival and risk factors for recurrence. Ann Surg Oncol2012;19:41864192.

    • Search Google Scholar
    • Export Citation
  • 116.

    IzadmehrSLeapmanMHobbsAR. Clinical characteristics and outcomes of HIV-seropositive men treated with surgery for prostate cancer. Int Urol Nephrol2016;48:16391645.

    • Search Google Scholar
    • Export Citation
  • 117.

    SilbersteinJLParsonsJKPalazzi-ChurasK. Robot-assisted laparoscopic radical prostatectomy in men with human immunodeficiency virus. Prostate Cancer Prostatic Dis2010;13:328332.

    • Search Google Scholar
    • Export Citation
  • 118.

    SigelCCavalcantiMSDanielT. Clinicopathologic features of colorectal carcinoma in HIV-positive patients. Cancer Epidemiol Biomarkers Prev2016;25:10981104.

    • Search Google Scholar
    • Export Citation
  • 119.

    Di BenedettoFTarantinoGErcolaniG. Multicenter Italian experience in liver transplantation for hepatocellular carcinoma in HIV-infected patients. Oncologist2013;18:592599.

    • Search Google Scholar
    • Export Citation
  • 120.

    BizerLSPettorinoRAshikariA. Emergency abdominal operations in the patient with acquired immunodeficiency syndrome. J Am Coll Surg1995;180:205209.

    • Search Google Scholar
    • Export Citation
  • 121.

    CacalaSRMafanaEThomsonSRSmithA. Prevalence of HIV status and CD4 counts in a surgical cohort: their relationship to clinical outcome. Ann R Coll Surg Engl2006;88:4651.

    • Search Google Scholar
    • Export Citation
  • 122.

    HarrisHWSchecterWP. Surgical risk assessment and management in patients with HIV disease. Gastroenterol Clin North Am1997;26:377391.

    • Search Google Scholar
    • Export Citation
  • 123.

    MadibaTEMuckartDJThomsonSR. Human immunodeficiency disease: how should it affect surgical decision making?World J Surg2009;33:899909.

    • Search Google Scholar
    • Export Citation
  • 124.

    YiiMKSaunderAScottDF. Abdominal surgery in HIV/AIDS patients: indications, operative management, pathology and outcome. Aust N Z J Surg1995;65:320326.

    • Search Google Scholar
    • Export Citation
  • 125.

    FaustoJAJrSelwynPA. Palliative care in the management of advanced HIV/AIDS. Prim Care2011;38:311326.

  • 126.

    LeeJYDhakalICasperC. Risk of cancer among commercially insured HIV-infected adults on antiretroviral therapy. J Cancer Epidemiol2016;2016:2138259.

    • Search Google Scholar
    • Export Citation
  • 127.

    ShielsMSPfeifferRMHallHI. Proportions of Kaposi sarcoma, selected non-Hodgkin lymphomas, and cervical cancer in the United States occurring in persons with AIDS, 1980–2007. JAMA2011;305:14501459.

    • Search Google Scholar
    • Export Citation
  • 128.

    TrepkaMJAufRFennieKP. Deaths due to screenable cancers among people living with HIV infection, Florida, 2000–2014. Am J Prev Med2017;53:705709.

    • Search Google Scholar
    • Export Citation
  • 129.

    LevineAMSeabergECHessolNA. HIV as a risk factor for lung cancer in women: data from the Women's Interagency HIV Study. J Clin Oncol2010;28:15141519.

    • Search Google Scholar
    • Export Citation
  • 130.

    KirkGDMerloCO'DriscollP. HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis2007;45:103110.

    • Search Google Scholar
    • Export Citation
  • 131.

    SigelKWisniveskyJCrothersK. Immunological and infectious risk factors for lung cancer in US veterans with HIV: a longitudinal cohort study. Lancet HIV2017;4:e6773.

    • Search Google Scholar
    • Export Citation
  • 132.

    ReddyKPKongCYHyleEP. Lung cancer mortality associated with smoking and smoking cessation among people living with HIV in the United States. JAMA Intern Med2017;177:16131621.

    • Search Google Scholar
    • Export Citation
  • 133.

    National Lung Screening Trial Research TAberleDRAdamsAM. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med2011;365:395409.

    • Search Google Scholar
    • Export Citation
  • 134.

    National Lung Screening Trial Research TChurchTRBlackWC. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med2013;368:19801991.

    • Search Google Scholar
    • Export Citation
  • 135.

    HulbertAHookerCMKerulyJC. Prospective CT screening for lung cancer in a high-risk population: HIV-positive smokers. J Thorac Oncol2014;9:752759.

    • Search Google Scholar
    • Export Citation
  • 136.

    MakinsonAEymard-DuvernaySRaffiF. Feasibility and efficacy of early lung cancer diagnosis with chest computed tomography in HIV-infected smokers. AIDS2016;30:573582.

    • Search Google Scholar
    • Export Citation
  • 137.

    RonitAKristensenTKlitboDM. Incidental lung cancers and positive computed tomography images in people living with HIV. AIDS2017;31:19731977.

    • Search Google Scholar
    • Export Citation
  • 138.

    PowlesTThirwellCNewsom-DavisT. Does HIV adversely influence the outcome in advanced non-small-cell lung cancer in the era of HAART?Br J Cancer2003;89:457459.

    • Search Google Scholar
    • Export Citation
  • 139.

    LeeJYMoorePCLensingSY. Impact of HIV infection on Medicare beneficiaries with lung cancer. J Cancer Epidemiol2012;2012:706469.

  • 140.

    LeeJYMoorePCSteligaMA. Do HIV-infected non-small cell lung cancer patients receive guidance-concordant care?Med Care2013;51:10631068.

    • Search Google Scholar
    • Export Citation
  • 141.

    SunejaGShielsMSMelvilleSK. Disparities in the treatment and outcomes of lung cancer among HIV-infected individuals. AIDS2013;27:459468.

    • Search Google Scholar
    • Export Citation
  • 142.

    HookerCMMeguidRAHulbertA. Human immunodeficiency virus infection as a prognostic factor in surgical patients with non-small cell lung cancer. Ann Thorac Surg2012;93:405412.

    • Search Google Scholar
    • Export Citation
  • 143.

    PalefskyJMHollyEARalstonMLJayN. Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men. J Infect Dis1998;177:361367.

    • Search Google Scholar
    • Export Citation
  • 144.

    Colon-LopezVShielsMSMachinM. Anal cancer risk among people with HIV infection in the United States. J Clin Oncol2018;13:6875.

  • 145.

    PikettyCSelinger-LenemanHBouvierAM. Incidence of HIV-related anal cancer remains increased despite long-term combined antiretroviral treatment: results from the french hospital database on HIV. J Clin Oncol2012;30:43604366.

    • Search Google Scholar
    • Export Citation
  • 146.

    DuncanKCChanKJChiuCG. HAART slows progression to anal cancer in HIV-infected MSM. AIDS2015;29:305311.

  • 147.

    LiboisAFeoliFNkuizeM. Prolonged antiretroviral therapy is associated with fewer anal high-grade squamous intraepithelial lesions in HIV-positive MSM in a cross-sectional study. Sex Transm Infect2017;93:1517.

    • Search Google Scholar
    • Export Citation
  • 148.

    GaisaMSigelKHandJGoldstoneS. High rates of anal dysplasia in HIV-infected men who have sex with men, women, and heterosexual men. AIDS2014;28:215222.

    • Search Google Scholar
    • Export Citation
  • 149.

    BerryJMJayNCranstonRD. Progression of anal high-grade squamous intraepithelial lesions to invasive anal cancer among HIV-infected men who have sex with men. Int J Cancer2014;134:11471155.

    • Search Google Scholar
    • Export Citation
  • 150.

    ScholefieldJHCastleMTWatsonNF. Malignant transformation of high-grade anal intraepithelial neoplasia. Br J Surg2005;92:11331136.

  • 151.

    TinmouthJPeevaVAmareH. Progression from perianal high-grade anal intraepithelial neoplasia to anal cancer in HIV-positive men who have sex with men. Dis Colon Rectum2016;59:836842.

    • Search Google Scholar
    • Export Citation
  • 152.

    WatsonAJSmithBBWhiteheadMR. Malignant progression of anal intra-epithelial neoplasia. ANZ J Surg2006;76:715717.

  • 153.

    GautierMBrochardCLionA. High-grade anal intraepithelial neoplasia: progression to invasive cancer is not a certainty. Dig Liver Dis2016;48:806811.

    • Search Google Scholar
    • Export Citation
  • 154.

    GoldstoneSEJohnstoneAAMoshierEL. Long-term outcome of ablation of anal high-grade squamous intraepithelial lesions: recurrence and incidence of cancer. Dis Colon Rectum2014;57:316323.

    • Search Google Scholar
    • Export Citation
  • 155.

    BarrosoLF. Anal cancer screening. Lancet Oncol2012;13:e278279; author reply e280.

  • 156.

    PalefskyJBerryJMJayN. Anal cancer screening. Lancet Oncol2012;13:e279280; author reply e280.

  • 157.

    ParkIUPalefskyJM. Evaluation and management of anal intraepithelial neoplasia in HIV-negative and HIV-positive men who have sex with men. Curr Infect Dis Rep2010;12:126133.

    • Search Google Scholar
    • Export Citation
  • 158.

    RoarkR. The need for anal dysplasia screening and treatment programs for HIV-infected men who have sex with men: a review of the literature. J Assoc Nurses AIDS Care2011;22:433443.

    • Search Google Scholar
    • Export Citation
  • 159.

    ScholefieldJHHarrisDRadcliffeA. Guidelines for management of anal intraepithelial neoplasia. Colorectal Dis2011;13(Suppl 1):310.

  • 160.

    WentzensenN. Screening for anal cancer: endpoints needed. Lancet Oncol2012;13:438440.

  • 161.

    XuJZhouH. Screening for anal cancer in HIV positive patients: should we make it a standard-of-care[published online September 27 2017]?J Invest Surg2017doi: 10.1080/08941939.2017.1369608

    • Search Google Scholar
    • Export Citation
  • 162.

    AlamNNWhiteDANarangSK. Systematic review of guidelines for the assessment and management of high-grade anal intraepithelial neoplasia (AIN II/III). Colorectal Dis2016;18:135146.

    • Search Google Scholar
    • Export Citation
  • 163.

    HartschuhWBreitkopfCLenhardB. S1 guideline: anal intraepithelial neoplasia (AIN) and perianal intraepithelial neoplasia (PAIN). J Dtsch Dermatol Ges2011;9:256258.

    • Search Google Scholar
    • Export Citation
  • 164.

    SteeleSRVarmaMGMeltonGB. Practice parameters for anal squamous neoplasms. Dis Colon Rectum2012;55:735749.

  • 165.

    JohnstoneAASilveraRGoldstoneSE. Targeted ablation of perianal high-grade dysplasia in men who have sex with men: an alternative to mapping and wide local excision. Dis Colon Rectum2015;58:4552.

    • Search Google Scholar
    • Export Citation
  • 166.

    SmulianAGMooreDMRobertsonJCKralovicSM. Phase I study demonstrates safety and tolerability of radiofrequency ablation (RFA) of the anal mucosa. HIV Clin Trials2014;15:3644.

    • Search Google Scholar
    • Export Citation
  • 167.

    WillemsNLiboisANkuizeM. Treatment of anal dysplasia in HIV-positive men who have sex with men in a large AIDS reference centre. Acta Clin Belg2017;72:2935.

    • Search Google Scholar
    • Export Citation
  • 168.

    RichelOde VriesHJvan NoeselCJ. Comparison of imiquimod, topical fluorouracil, and electrocautery for the treatment of anal intraepithelial neoplasia in HIV-positive men who have sex with men: an open-label, randomised controlled trial. Lancet Oncol2013;14:346353.

    • Search Google Scholar
    • Export Citation
  • 169.

    BryantAKMudgwayRHuynh-LeMP. Effect of CD4 count on treatment toxicity and tumor recurrence in human immunodeficiency virus-positive patients with anal cancer. Intl J Rad Onc Biol Phys2018;100:479485.

    • Search Google Scholar
    • Export Citation
  • 170.

    BryantAKHuynh-LeMPSimpsonDR. Association of HIV status with outcomes of anal squamous cell carcinoma in the era of highly active antiretroviral therapy. JAMA Oncol2018;4:120122.

    • Search Google Scholar
    • Export Citation
  • 171.

    GrewDBittermanDLeichmanCG. HIV infection is associated with poor outcomes for patients with anal cancer in the highly active antiretroviral therapy era. Dis Colon Rectum2015;58:11301136.

    • Search Google Scholar
    • Export Citation
  • 172.

    Oehler-JanneCHuguetFProvencherS. HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy. J Clin Oncol2008;26:25502557.

    • Search Google Scholar
    • Export Citation
  • 173.

    WhiteECKhodayariBEricksonKT. Comparison of toxicity and treatment outcomes in HIV-positive versus HIV-negative patients with squamous cell carcinoma of the anal canal. Am J Clin Oncol2014;40:386392.

    • Search Google Scholar
    • Export Citation
  • 174.

    MartinDBalermpasPFokasE. Are there HIV-specific differences for anal cancer patients treated with standard chemoradiotherapy in the era of combined antiretroviral therapy?Clin Oncol (R Coll Radiol)2017;29:248255.

    • Search Google Scholar
    • Export Citation
  • 175.

    PappouEPMagruderJTFuT. Prognostic and predictive clinicopathologic factors of squamous anal canal cancer in HIV-positive and HIV-negative patients: does HAART influence outcomes?World J Surg2018;42:876883.

    • Search Google Scholar
    • Export Citation
  • 176.

    OliveiraSCMonizCMRiechelmannR. Phase II study of capecitabine in substitution of 5-FU in the chemoradiotherapy regimen for patients with localized squamous cell carcinoma of the anal canal. J Gastrointest Cancer2016;47:7581.

    • Search Google Scholar
    • Export Citation
  • 177.

    MorrisVKSalemMENimeiriH. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol2017;18:446453.

    • Search Google Scholar
    • Export Citation
  • 178.

    GargMLeeJYKachnicLA. Phase II trials of cetuximab (CX) plus cisplatin (CDDP), 5-fluorouracil (5-FU) and radiation (RT) in immunocompetent (ECOG 3205) and HIV-positive (AMC045) patients with squamous cell carcinoma of the anal canal (SCAC): safety and preliminary efficacy results [abstract]. J Clin Oncol2012;30(15 Suppl):Abstract 4030.

    • Search Google Scholar
    • Export Citation
  • 179.

    GargMKZhaoFSparanoJA. Cetuximab plus chemoradiotherapy in immunocompetent patients with anal carcinoma: a phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group trial (E3205). J Clin Oncol2017;35:718726.

    • Search Google Scholar
    • Export Citation
  • 180.

    SparanoJALeeJYPalefskyJ. Cetuximab plus chemoradiotherapy for HIV-associated anal carcinoma: a phase II AIDS Malignancy Consortium trial. J Clin Oncol2017;35:727733.

    • Search Google Scholar
    • Export Citation
  • 181.

    BiggarRJJaffeESGoedertJJ. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood2006;108:37863791.

  • 182.

    KowalkowskiMAMimsMPAmiranES. Effect of immune reconstitution on the incidence of HIV-related Hodgkin lymphoma. PLoS One2013;8:e77409.

  • 183.

    ManiHJaffeES. Hodgkin lymphoma: an update on its biology with new insights into classification. Clin Lymphoma Myeloma2009;9:206216.

  • 184.

    RuizMParsonsCColeJ. Characterization of HIV-associated Hodgkin's lymphoma in HIV-infected patients: a single-center experience. J Int Assoc Physicians AIDS Care (Chic)2012;11:234238.

    • Search Google Scholar
    • Export Citation
  • 185.

    SorigueMGarciaOTapiaG. HIV-infection has no prognostic impact on advanced-stage Hodgkin lymphoma. AIDS2017;31:14451449.

  • 186.

    Diez-MartinJLBalsalobrePReA. Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation. Blood2009;113:60116014.

    • Search Google Scholar
    • Export Citation
  • 187.

    XicoyBRiberaJMMirallesP. Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma. Haematologica2007;92:191198.

    • Search Google Scholar
    • Export Citation
  • 188.

    SerrainoDCarboneAFranceschiSTirelliU. Increased frequency of lymphocyte depletion and mixed cellularity subtypes of Hodgkin's disease in HIV-infected patients. Italian Cooperative Group on AIDS and Tumours. Eur J Cancer1993;29A:19481950.

    • Search Google Scholar
    • Export Citation
  • 189.

    TirelliUErranteDDolcettiR. Hodgkin's disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors. J Clin Oncol1995;13:17581767.

    • Search Google Scholar
    • Export Citation
  • 190.

    BessonCLancarRPrevotS. High risk features contrast with favorable outcomes in HIV-associated Hodgkin lymphoma in the modern cART era, ANRS CO16 LYMPHOVIR cohort. Clin Infect Dis2015;61:14691475.

    • Search Google Scholar
    • Export Citation
  • 191.

    ShahBKSubramaniamSPeaceDGarciaC. HIV-associated primary bone marrow Hodgkin's lymphoma: a distinct entity?J Clin Oncol2010;28:e459460.

    • Search Google Scholar
    • Export Citation
  • 192.

    O'NeillAMikeschKFritschK. Outcomes for HIV-positive patients with primary central nervous system lymphoma after high-dose chemotherapy and auto-SCT. Bone Marrow Transplant2015;50:9991000.

    • Search Google Scholar
    • Export Citation
  • 193.

    GlaserSLClarkeCAGulleyML. Population-based patterns of human immunodeficiency virus-related Hodgkin lymphoma in the Greater San Francisco Bay Area, 1988–1998. Cancer2003;98:300309.

    • Search Google Scholar
    • Export Citation
  • 194.

    MontotoSShawKOkosunJ. HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. J Clin Oncol2012;30:41114116.

    • Search Google Scholar
    • Export Citation
  • 195.

    ShielsMSKoritzinskyEHClarkeCA. Prevalence of HIV Infection among U.S. Hodgkin lymphoma cases. Cancer Epidemiol Biomarkers Prev2014;23:274281.

    • Search Google Scholar
    • Export Citation
  • 196.

    HoffmannCChowKUWolfE. Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's disease. Br J Haematol2004;125:455462.

    • Search Google Scholar
    • Export Citation
  • 197.

    OlszewskiAJCastilloJJ. Outcomes of HIV-associated Hodgkin lymphoma in the era of antiretroviral therapy. AIDS2016;30:787796.

  • 198.

    HanXJemalAHullandE. HIV infection and survival of lymphoma patients in the era of highly active antiretroviral therapy. Cancer Epidemiol Biomarkers Prev2017;26:303311.

    • Search Google Scholar
    • Export Citation
  • 199.

    SpinaMGabarreJRossiG. Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood2002;100:19841988.

    • Search Google Scholar
    • Export Citation
  • 200.

    HartmannPRehwaldUSalzbergerB. BEACOPP therapeutic regimen for patients with Hodgkin's disease and HIV infection. Ann Oncol2003;14:15621569.

    • Search Google Scholar
    • Export Citation
  • 201.

    HentrichMBergerMWyenC. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. J Clin Oncol2012;30:41174123.

    • Search Google Scholar
    • Export Citation
  • 202.

    EzzatHMCheungMCHicksLK. Incidence, predictors and significance of severe toxicity in patients with human immunodeficiency virus-associated Hodgkin lymphoma. Leuk Lymphoma2012;53:23902396.

    • Search Google Scholar
    • Export Citation
  • 203.

    SpitzerTRAmbinderRFLeeJY. Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020. Biol Blood Marrow Transplant2008;14:5966.

    • Search Google Scholar
    • Export Citation
  • 204.

    BalsalobrePDiez-MartinJLReA. Autologous stem-cell transplantation in patients with HIV-related lymphoma. J Clin Oncol2009;27:21922198.

    • Search Google Scholar
    • Export Citation
  • 205.

    AlvarnasJCLe RademacherJWangY. Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial. Blood2016;128:10501058.

    • Search Google Scholar
    • Export Citation
  • 206.

    OkosunJWarbeyVShawK. Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection. AIDS2012;26:861865.

    • Search Google Scholar
    • Export Citation
  • 207.

    DanilovAVLiHPressOW. Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 phase 2 trial. Leuk Lymphoma2017;58:461465.

    • Search Google Scholar
    • Export Citation
  • 208.

    JohnsonPFedericoMKirkwoodA. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma. N Engl J Med2016;374:24192429.

    • Search Google Scholar
    • Export Citation
  • 209.

    AndrieuJMRoithmannSTouraniJM. Hodgkin's disease during HIV1 infection: the French registry experience. French Registry of HIV-associated Tumors. Ann Oncol1993;4:635641.

    • Search Google Scholar
    • Export Citation
  • 210.

    WalboomersJMJacobsMVManosMM. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol1999;189:1219.

    • Search Google Scholar
    • Export Citation
  • 211.

    AdebamowoSNOlawandeOFamootoA. Persistent low-risk and high-risk human papillomavirus infections of the uterine cervix in HIV-negative and HIV-positive women. Front Public Health2017;5:178.

    • Search Google Scholar
    • Export Citation
  • 212.

    McDonaldACTergasAIKuhnL. Distribution of human papillomavirus genotypes among HIV-positive and HIV-negative women in Cape Town, South Africa. Front Oncol2014;4:48.

    • Search Google Scholar
    • Export Citation
  • 213.

    AbrahamAGD'SouzaGJingY. Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr2013;62:405413.

    • Search Google Scholar
    • Export Citation
  • 214.

    ChenYCLiCYLiuHY. Effect of antiretroviral therapy on the incidence of cervical neoplasia among HIV-infected women: a population-based cohort study in Taiwan. AIDS2014;28:709715.

    • Search Google Scholar
    • Export Citation
  • 215.

    AdlerDHKakinamiLModisenyaneT. Increased regression and decreased incidence of human papillomavirus-related cervical lesions among HIV-infected women on HAART. AIDS2012;26:16451652.

    • Search Google Scholar
    • Export Citation
  • 216.

    HeardIPotardVCostagliolaD. Limited impact of immunosuppression and HAART on the incidence of cervical squamous intraepithelial lesions in HIV-positive women. Antivir Ther2006;11:10911096.

    • Search Google Scholar
    • Export Citation
  • 217.

    MenonSRossiRZdraveskaN. Associations between highly active antiretroviral therapy and the presence of HPV, premalignant and malignant cervical lesions in sub-Saharan Africa, a systematic review: current evidence and directions for future research. BMJ Open2017;7:e015123.

    • Search Google Scholar
    • Export Citation
  • 218.

    KellyHWeissHABenaventeY. Association of antiretroviral therapy with high-risk human papillomavirus, cervical intraepithelial neoplasia, and invasive cervical cancer in women living with HIV: a systematic review and meta-analysis. Lancet HIV2018;5:e4558.

    • Search Google Scholar
    • Export Citation
  • 219.

    International Collaboration on HIV Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst2000;92:18231830.

    • Search Google Scholar
    • Export Citation
  • 220.

    SantessoNMustafaRASchunemannHJ. World Health Organization Guidelines for treatment of cervical intraepithelial neoplasia 2-3 and screen-and-treat strategies to prevent cervical cancer. Int J Gynaecol Obstet2016;132:252258.

    • Search Google Scholar
    • Export Citation
  • 221.

    ForhanSEGodfreyCCWattsDHLangleyCL. A systematic review of the effects of visual inspection with acetic acid, cryotherapy, and loop electrosurgical excision procedures for cervical dysplasia in HIV-infected women in low- and middle-income countries. J Acquir Immune Defic Syndr2015;68(Suppl 3):S350356.

    • Search Google Scholar
    • Export Citation
  • 222.

    HankEHoqueMEZunguL. Cervical precancerous lesions and cancer among patients in the gynaecology outpatient department at a tertiary hospital in South Africa. Asian Pac J Cancer Prev2013;14:49034906.

    • Search Google Scholar
    • Export Citation
  • 223.

    HeardIPotardVFoulotH. High rate of recurrence of cervical intraepithelial neoplasia after surgery in HIV-positive women. J Acquir Immune Defic Syndr2005;39:412418.

    • Search Google Scholar
    • Export Citation
  • 224.

    KreitchmannRBajottoHda SilvaDAFuchsSC. Squamous intraepithelial lesions in HIV-infected women: prevalence, incidence, progression and regression. Arch Gynecol Obstet2013;288:11071113.

    • Search Google Scholar
    • Export Citation
  • 225.

    McClungECBlumenthalPD. Efficacy, safety, acceptability and affordability of cryotherapy: a review of current literature. Minerva Ginecol2012;64:149171.

    • Search Google Scholar
    • Export Citation
  • 226.

    ReimersLLSotardiSDanielD. Outcomes after an excisional procedure for cervical intraepithelial neoplasia in HIV-infected women. Gynecol Oncol2010;119:9297.

    • Search Google Scholar
    • Export Citation
  • 227.

    FoulotHHeardIPotardV. Surgical management of cervical intraepithelial neoplasia in HIV-infected women. Eur J Obstet Gynecol Reprod Biol2008;141:153157.

    • Search Google Scholar
    • Export Citation
  • 228.

    BamburyIMullingsAFletcherH. Cervical intraepithelial neoplasia in a cohort of HIV-positive women at the University Hospital of the West Indies: management and outcome. West Indian Med J2013;62:313317.

    • Search Google Scholar
    • Export Citation
  • 229.

    CejtinHEZimmermanLMathewsMPatelA. Predictors of persistent or recurrent disease after loop electrosurgical excision procedure. J Low Genit Tract Dis2017;21:5963.

    • Search Google Scholar
    • Export Citation
  • 230.

    SmithJSSanusiBSwartsA. A randomized clinical trial comparing cervical dysplasia treatment with cryotherapy vs loop electrosurgical excision procedure in HIV-seropositive women from Johannesburg, South Africa. Am J Obstet Gynecol2017;217:183.e1183.e11.

    • Search Google Scholar
    • Export Citation
  • 231.

    NtekimACampbellORothenbacherD. Optimal management of cervical cancer in HIV-positive patients: a systematic review. Cancer Med2015;4:13811393.

    • Search Google Scholar
    • Export Citation
  • 232.

    SimondsHMNeugutAIJacobsonJS. HIV status and acute hematologic toxicity among patients with cervix cancer undergoing radical chemoradiation. Int J Gynecol Cancer2015;25:884890.

    • Search Google Scholar
    • Export Citation
  • 233.

    UldrickTSIsonGRudekMA. Modernizing clinical trial eligibility criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research HIV Working Group. J Clin Oncol2017;35:37743780.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 1 1 0
Full Text Views 1544 1544 76
PDF Downloads 399 399 25
EPUB Downloads 0 0 0